Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy
Completed
- Conditions
- Chronic Hepatitis c
- Registration Number
- NCT03348059
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in Hepatitis C virus (HCV)-infected patients receiving direct-acting antiviral treatment
- Detailed Description
Presence of anti-E1E2 antibodies was previously associated with spontaneous cure of hepatitis C virus (HCV). The hypothesis was to check whether baseline anti-E1E2 antibodies could predict virological outcome in HCV-infected patients receiving direct-acting antiviral treatment
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 103
Inclusion Criteria
- 18 years of age or older
- HCV patients treated with direct-acting antiviral treatment
- Patients with a prior treatment blood sample
- Patients with sustained virological response or virological relapse
Read More
Exclusion Criteria
- HIV or hepatitis B virus (HBV) coinfection
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with positive anti-E1E2 antibody level at treatment initiation Baseline (treatment initiation day) Anti-E1E2 antibody levels were determined using optical densities obtained after dilution of patients' serum samples at 1/250 and 1/500. Samples with anti-E1E2 levels above 950 (OD value× 1000) were considered positive
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Croix-Rousse Hospital, Hospices Civils de Lyon
🇫🇷Lyon, France